Clinical trial

COVID-19 Booster and IIV Schedule in Immunocompromised Hosts

NCT06599658

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2024-11-20

PhasePHASE2

Study timeline

Study start (actual)2024-11-20Date precision: day

Registry last updated2026-03-10

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

COVID 19unresolved

Influenzaunresolved

Rheumatoid Arthritis (RA)unresolved

Systemic Lupus Erthematosusunresolved

Inflammatory Bowel Diseaseunresolved

Solid Organ Transplant Recipientsunresolved

Immunocompromised Hostunresolved

People Living With HIVunresolved

Interventions

Inactivated influenza vaccine (IIV) at baselineBIOLOGICAL

COVID-19 Vaccines at a 3-month intervalBIOLOGICAL

Inactivated influenza vaccine at Month 1BIOLOGICAL

COVID-19 Vaccines at a 6-month intervalBIOLOGICAL

Sponsors & collaborators

McGill University Health Centre/Research Institute of the McGill University Health Centrelead sponsor

Centre hospitalier de l'Université de Montréal (CHUM)collaborator

Mapped research locations

MontrealQuebec, Canada3

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06599658 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.